Evicenter
MarkdownMedical informationP&T meetings
Ifezuntirgene inilparvovec (AMT-130)

Huntington's disease

Manufacturer
uniQure
Launch
Not announced
Last updated
291 sources

Section 3 of 6

Product information and disease description

383 evidence topics · 249 sources

Product description

Phase of product development

Launch

No evidence found.

PRIority MEdicines (PRIME) designation

No evidence found.

Product information

Generic, brand name and therapeutic class of product
Product name, product code, and descriptive name in the EU clinical trial record
Brand name

No evidence found.

Manufacturing: contract manufacturing by Genezen after the 2024 facility sale
Dosage forms and strengths
Pharmaceutical form and route of administration
Pharmaceutical form and concentrations in the European phase Ib/II study
FieldQuoted record
Pharmaceutical form“Solution for infusion”
Concentration, first IMP“2 x 10e12 gc/mL”
Concentration, second IMP“2 x 10e13 gc/mL”
Formulation composition, fill volume, and storage conditions

No evidence found.

Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification
EU classification: advanced therapy investigational medicinal product, gene therapy
FieldQuoted record
Advanced Therapy IMP (ATIMP)“Yes”
Gene therapy medical product“Yes”
Committee on Advanced therapies (CAT) has issued a classification for this product“No”
AHFS and Anatomical Therapeutic Chemical classification

No evidence found.

Indication
Pharmacology
Mechanism of action
Pharmacodynamics
Exploratory pharmacodynamic biomarkers in the U.S. study: mutant huntingtin and neurofilament light chain in cerebrospinal fluid
Pharmacokinetics
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions

Not applicable.

Special populations
Juvenile Huntington's disease

No evidence found.

Dosing in hepatic impairment, renal impairment, or older adults

No evidence found.

Drug/Drug, drug/disease interactions
Effects of other drugs on Ifezuntirgene inilparvovec
Effects of Ifezuntirgene inilparvovec on other drugs

No evidence found.

Dosing and administration
Dosage
Infusion volume and concentration of the clinical dose

No evidence found.

Administration
Access and distribution
Specialty distribution, risk evaluation and mitigation strategy, and payer coverage

No evidence found.

Co-prescribed/Concomitant therapies
Agents, doses, and duration of the immunosuppression regimen

No evidence found.

Effect of Ifezuntirgene inilparvovec on quality measures
Ifezuntirgene inilparvovec-specific effect on quality measures

No evidence found.

Product comparison
Registered trials of investigational disease-modifying therapies: mechanism, comparator, and design
TrialInterventionMechanism of actionPopulationComparisonStudy designEstimated enrolment
INVEST-HD (NCT07326709)“Votoplam”View highlighted excerpt for this quote“Small molecule splicing modulator”View highlighted excerpt for this quote“Early HD (CAG ≥40, UHDRS TFC=13, TMS 7-25, IS ≥90”View highlighted excerpt for this quote“Placebo”View highlighted excerpt for this quote“Randomized, double-blind, placebo-controlled, parallel-group (phase III)”View highlighted excerpt for this quote“770”View highlighted excerpt for this quote
FALCON-HD (NCT07378644)“SKY-0515”View highlighted excerpt for this quote“mRNA splicing modulator designed to lower mHTT and PMS1”View highlighted excerpt for this quote“Early HD; UHDRS TFC ≥10, TMS ≥6, IS ≥70”View highlighted excerpt for this quote“Placebo”View highlighted excerpt for this quote“Randomized, double-blind, placebo-controlled, dose-ranging, parallel-group (phase II/III)”View highlighted excerpt for this quote“400”View highlighted excerpt for this quote
NCT06826612“Intraparenchymal infusion of SPK-10001 into caudate and putamen bilaterally”View highlighted excerpt for this quote“AAV-mediated gene therapy delivering therapeutic construct to striatum to modify disease progression”View highlighted excerpt for this quote“HD-ISS stage 1 or 2 HD; UHDRS TFC ≥11”View highlighted excerpt for this quote“Placebo/sham surgery”View highlighted excerpt for this quote“Randomized, sequential dose-escalation, quadruple-masked, parallel assignment”View highlighted excerpt for this quote“53”View highlighted excerpt for this quote
NCT06585449“ALN-HTT02”View highlighted excerpt for this quote“RNA interference selectively targeting exon 1 of HTT mRNA”View highlighted excerpt for this quote“HD-ISS stage 2 or early stage 3 HD”View highlighted excerpt for this quote“Placebo”View highlighted excerpt for this quote“Randomized, double-blind, parallel assignment, single dose”View highlighted excerpt for this quote“54”View highlighted excerpt for this quote
POINT-HD (NCT07246941)“RG6496”View highlighted excerpt for this quote“Intrathecally administered HTT-lowering therapy; SNP-targeted approach”View highlighted excerpt for this quote“HD gene-expansion carrierss with target SNP, CAG >39, UHDRS TFC ≥10, TMS ≥6, IS ≥70”View highlighted excerpt for this quote“Placebo”View highlighted excerpt for this quote“Randomized, placebo-controlled, single-ascending-dose study with open-label extension (phase I)”View highlighted excerpt for this quote“40”View highlighted excerpt for this quote
VO659-CT01 (NCT05822908)“Intrathecal administration of VO659”View highlighted excerpt for this quote“ASO targeting mutant HTT and ataxin RNA to reduce toxic protein levels”View highlighted excerpt for this quote“SCA1, SCA3, HD”View highlighted excerpt for this quote“None”View highlighted excerpt for this quote“Open-label, non-randomized”View highlighted excerpt for this quote“68”View highlighted excerpt for this quote
NCT07344519“ER2001”View highlighted excerpt for this quote“Small interfering RNA”View highlighted excerpt for this quote“Adults with early manifest HD who completed study ER2001-001”View highlighted excerpt for this quote“None”View highlighted excerpt for this quote“Open-label, dose-escalation, single-group (phase I)”View highlighted excerpt for this quote“8”View highlighted excerpt for this quote
GENERATION HD2 (NCT05686551)“Tominersen”View highlighted excerpt for this quote“Non-allele-selective ASO”View highlighted excerpt for this quote“Prodromal and early HD”View highlighted excerpt for this quote“Placebo”View highlighted excerpt for this quote“Randomized, double-blind, dose-finding trial”View highlighted excerpt for this quote“360”View highlighted excerpt for this quote
SELECT-HD (NCT05032196)“WVE-003”View highlighted excerpt for this quote“Allele-selective ASO”View highlighted excerpt for this quote“Early HD”View highlighted excerpt for this quote“Placebo”View highlighted excerpt for this quote“Randomized, double-blind, placebo-controlled, combined single ascending dose/multiple ascending dose trial”View highlighted excerpt for this quote“36”View highlighted excerpt for this quote
PRECISE-HD (NCT07609108)“Pridopidine”View highlighted excerpt for this quote“Sigma-1 receptor activation”View highlighted excerpt for this quote“Manifest HD (not receiving antidopaminergic medications for ≥6 months before screening)”View highlighted excerpt for this quote“Placebo”View highlighted excerpt for this quote“Randomized, double-blind, placebo-controlled, parallel-group trial with 52-week treatment period followed by a 2-year open-label extension (phase III)”View highlighted excerpt for this quote“400”View highlighted excerpt for this quote
Tominersen: GENERATION HD1 biomarkers, adverse events, and post hoc subgroup analyses

“The changes in mutant HTT levels in CSF were consistent with dose regimen–dependent decreases and concomitant increases in ventricular volume” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The absence of whole-brain volume loss in the context of ventricular expansion and the absence of a correlation between the change in CSF NfL levels and change in ventricular volume suggest that increases in ventricular volume do not reflect increased atrophy” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A transient increase was seen in CSF NfL levels in the every-8-week tominersen group at week 21; although neuroaxonal damage may be implicated, increased levels of leukocytes and total protein in CSF in some participants suggest an inflammatory component” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“More adverse events occurred in the participants in the every-8-week tominersen group than in those in the placebo group and the every-16-week tominersen group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The results of post hoc analyses support the hypothesis that younger participants (who have less disease burden) may benefit from tominersen therapy” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“this hypothesis is currently being tested in a phase 2 dose-finding trial (GENERATION HD2; NCT05686551).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Direct head-to-head comparison of ifezuntirgene inilparvovec with an approved or investigational therapy

No evidence found.

Place of product in therapy

Disease description

Definition and etiology
CAG repeat length thresholds
Allele categoryCAG repeat length
Normal alleles“26 or fewer CAG repeats”
Intermediate alleles“27 to 35 CAG repeats”
Reduced-penetrance HD-causing alleles“36 to 39 CAG repeats”
Full-penetrance HD-causing alleles“40 or more CAG repeats”
Epidemiology
Incidence of Huntington's disease
Prevalence of Huntington's disease
Natural history, survival, and mortality
Enroll-HD: prospective observational natural history study, annual visits, and periodic data releases

“Enroll-HD is now operating worldwide in 21 countries at 159 clinical sites across four continents” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Europe, North America, Latin America, and Australasia” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“and has recruited almost 25,000 participants” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Central to the clinical research platform is the Enroll-HD study (NCT01574053), a prospective longitudinal observational study that collects natural history data in HD gene-expansion carriers (HDGECs) and non-HDGEC controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The Enroll-HD platform has been designed with the benefit of experience gained from several foundational HD studies” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“REGISTRY, PREDICT-HD, COHORT, and TRACK-HD/Track On-HD (12–16).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At their annual study visit, each participant is required to complete a core battery of assessments; extended and optional assessments are completed at the discretion of the PI and participant, respectively (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“PDSs are prepared from the Enroll-HD study database every 1–2 years and include a large majority of the collected variables.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Pathophysiology
Genetic modifiers of onset: DNA repair genes identified by GWAS
Diagnosis
Clinical presentation - signs and symptoms
Long-term morbidity
Burden of Huntington's disease
Humanistic burden and health-related quality of life
Economic burden and healthcare resource utilization
Systematic review of cost-of-illness studies: annual costs by stage and cost type (2023 U.S. dollars)
Cost type and study“Early”View highlighted excerpt for this quote“Middle”View highlighted excerpt for this quote“Late”View highlighted excerpt for this quote
Inpatient, Divino“1150”View highlighted excerpt for this quote“5045”View highlighted excerpt for this quote“9216”View highlighted excerpt for this quote
Inpatient, Exuzides“1225”View highlighted excerpt for this quote“4250”View highlighted excerpt for this quote“22,228”View highlighted excerpt for this quote
Inpatient, Patel“791”View highlighted excerpt for this quote“3,070”View highlighted excerpt for this quote“65,465”View highlighted excerpt for this quote
Outpatient, Divino“2956”View highlighted excerpt for this quote“10,508”View highlighted excerpt for this quote“30,104”View highlighted excerpt for this quote
Outpatient, Exuzides“4736”View highlighted excerpt for this quote“10,361”View highlighted excerpt for this quote“13,665”View highlighted excerpt for this quote
Outpatient, Patel“5676”View highlighted excerpt for this quote“11639”View highlighted excerpt for this quote“6226”View highlighted excerpt for this quote
Drug, Divino“2483”View highlighted excerpt for this quote“4518”View highlighted excerpt for this quote“4838”View highlighted excerpt for this quote
Drug, Exuzides“15,663”View highlighted excerpt for this quote“16,790”View highlighted excerpt for this quote“23,944”View highlighted excerpt for this quote
Drug, Patel“6330”View highlighted excerpt for this quote“14149”View highlighted excerpt for this quote“13,108”View highlighted excerpt for this quote
Caregiving, Jones“6073”View highlighted excerpt for this quote“44,662”View highlighted excerpt for this quote“133,200”View highlighted excerpt for this quote
Caregiving, Silva-Pardes“6041”View highlighted excerpt for this quote“16,502”View highlighted excerpt for this quote“21,438”View highlighted excerpt for this quote
HDBOI study: design, participants, and costing methods

“The HDBOI study is a noninterventional, retrospective, cross-sectional, international burden of illness study of people with diagnosed HD in France, Germany, Italy, Spain, the UK, and the USA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 2094 PwHD were enrolled in the HDBOI study, 40% of whom (n = 846) were classified as ES, 34% as MS (n = 701), and 26% as AS (n = 547; Table 1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Information regarding HD-related health care resource use used to compute direct medical costs was available for all 2094 PwHD. Information on direct nonmedical costs was available for 359 PwHD and indirect costs for 436 PwHD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Costs are reported in 2020 euros for all outcomes” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“To minimize underestimation of costs due to potentially reduced care interactions during the coronavirus disease 2019 (COVID-19) pandemic, health care resource use (used to compute direct medical costs) was extracted for a set time period before the pandemic (March 2019 through March 2020).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“For actively employed PwHD and caregivers, productivity loss was quantified as the number of days missed from work due to HD in the past 3 months multiplied by the country average salary per day.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“For those unable to work due to HD, an opportunity cost was assigned based on 1 year of average salary per country.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

HDBOI study: cost drivers and mean annual cost components by stage (2020 euros)
Cost componentEarly stage, mean (SD) and nMid stage, mean (SD) and nAdvanced stage, mean (SD) and n
Consultations“€727 (€1216) n = 829”View highlighted excerpt for this quote“€767 (€975) n = 693”View highlighted excerpt for this quote“€1051 (€1335) n = 545”View highlighted excerpt for this quote
Hospital inpatient“€35,803 (€102,653) n = 28”View highlighted excerpt for this quote“€30,698 (€39,581) n = 23”View highlighted excerpt for this quote“€12,658 (€42,550) n = 60”View highlighted excerpt for this quote
Treatment“€6333 (€25,525) n = 667”View highlighted excerpt for this quote“€6539 (€28,257) n = 571”View highlighted excerpt for this quote“€7922 (€26,248) n = 454”View highlighted excerpt for this quote
Residential care“€41,879 (€46,946) n = 16”View highlighted excerpt for this quote“€56,673 (€40,806) n = 26”View highlighted excerpt for this quote“€45,977 (€31,915) n = 98”View highlighted excerpt for this quote
Professional caregiver“€1286 (€4355) n = 204”View highlighted excerpt for this quote“€2308 (€9831) n = 164”View highlighted excerpt for this quote“€2582 (€8632) n = 114”View highlighted excerpt for this quote
State support, patient“€841 (€2123) n = 204”View highlighted excerpt for this quote“€1199 (€2497) n = 164”View highlighted excerpt for this quote“€2677 (€3437) n = 114”View highlighted excerpt for this quote
Lost productivity, PwHD“€23,216 (€16,848) n = 75”View highlighted excerpt for this quote“€31,824 (€13,934) n = 109”View highlighted excerpt for this quote“€34,343 (€10,295) n = 98”View highlighted excerpt for this quote
Other countries: Israel, China, Peru, Brazil, and Germany
Economic impact of Huntington's disease on families
Informal care and caregiver productivity costs: HDBOI study (2020 euros)
Caregivers of people with advanced HD in North America: systematic literature review
Caregiver outcomeQuoted value
Mean time spent as primary carer (years)“10.2 years”
Total hours of formal care per week“43 hours”
Total hours of informal care per week“41 hours”
Prevented career progression“51%”
Prevented from working more hours“70%”
Overall work productivity loss“54%”
Economic impact of diagnostic testing

Approaches to treatment

Current treatment options and standard of care
VMAT2 inhibitors
Antipsychotics
Antidepressants and other psychiatric pharmacotherapy
Rehabilitation and nutritional therapies
Limitations of current therapies
Summary

In a review of disease-modifying interventions, none of the pharmacological interventions proved effective as a disease-modifying therapy for HD, and the Huntington's Disease Society of America states that there is currently no cure or treatment that can halt, slow, or reverse progression of the disease.

  • Chorea: in a review of 22 trials (1254 participants), only tetrabenazine showed clear efficacy for the control of chorea. An evidence-based review concluded that the data support only the use of VMAT2 inhibitors for specific motor symptoms. The prescribing information for tetrabenazine, deutetrabenazine, and valbenazine states that each can increase the risk of depression and suicidal thoughts and behavior in patients with HD, and tetrabenazine is contraindicated in patients who are actively suicidal or have untreated or inadequately treated depression. In the 12-week placebo-controlled tetrabenazine study, 10 of 54 patients (19%) reported depression or worsening depression compared with none of 30 placebo-treated patients; Total Chorea Scores returned to baseline at the Week 13 follow-up, 1 week after discontinuation, and measures of functional capacity and cognition showed no difference from placebo. The valbenazine prescribing information states that drug-induced parkinsonism can cause more functional disability than untreated chorea for some patients. Side effects of neuroleptics include apathy, sedation, akathisia, worsening of voluntary motor control, tardive dyskinesia, and neuroleptic malignant syndrome. One publication states that pharmacologic treatment of chorea remains underutilized in clinical practice.
  • Psychiatric symptoms: the evidence-based review found no eligible evidence to support specific treatments for depression, psychosis, irritability, apathy, or suicidality. A review of fifteen articles concluded that convincing evidence to guide practice is lacking, and one guideline states that its recommendations on mental health problems are based on expert opinion.
  • Cognitive symptoms: one guideline recommends no pharmacological treatment for cognitive symptoms.
  • Nonpharmacological care: the evidence-based review found no eligible evidence to support physiotherapy, occupational therapy, exercise, dietary, or surgical treatments.
  • Evidence base: among 376 therapeutic studies conducted between 1965 and 2015, the authors of that guideline found one grade A study.
Summary: investigational therapies and regulatory history of ifezuntirgene inilparvovec
  • Tominersen: in GENERATION HD1, treatment was stopped in March 2021 on the basis of an independent data monitoring committee's benefit-risk assessment, and the cUHDRS change at week 69 in the every-8-week group was significantly worse than placebo (−0.54 points, adjusted P=0.001). In GENERATION HD2, reductions in mHTT protein and NfL in 301 participants did not translate into a meaningful improvement in clinical outcomes, and Roche discontinued clinical development of tominersen.
  • Pridopidine: the primary and key secondary endpoints (change in TFC and cUHDRS at week 65) of the phase III PROOF-HD study were not met in the overall population. In its questions and answers on the withdrawal of the marketing authorisation application for pridopidine (Nurzigma), the European Medicines Agency noted that the validity and relevance of the subgroup results in patients not treated with antidopaminergic medicines had not been demonstrated.
  • Ifezuntirgene inilparvovec (AMT-130): the sponsor stated at its BLA submission that there are currently no approved therapies to delay the onset or slow the progression of HD. The sponsor reported that, at an RMAT Type B meeting, the FDA agreed that Phase I/II data compared with a natural history external control may serve as the primary basis for a BLA submission under the Accelerated Approval pathway. After a pre-BLA meeting held on October 29, 2025, the FDA conveyed that the Phase I/II data were currently unlikely to provide the primary evidence to support a BLA submission. Final minutes of a Type A meeting held on January 30, 2026 stated that the FDA could not agree that the Phase I/II data compared with an external control were sufficient, and the FDA strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study. After a subsequent Type B meeting, the FDA communicated that the 3-year analysis would be acceptable as the primary basis of a BLA for accelerated approval. The third quarter 2026 Form 10-Q states both that the submission was announced in September 2026 and that the BLA was submitted in August 2026 and accepted for review in October 2026; it reports the acceptance as announced on November 2, 2026. The application was granted Priority Review with a PDUFA target action date of May 1, 2027, and the 48-month topline results were not part of the BLA.
Place in treatment, anticipated use, and care setting
Summary: studied population and anticipated use
  • Studied population: the U.S. Phase I/II study and the European Phase Ib/II study use the same early manifest criteria, enrolling males and females aged 25 to 65 years with a definitive clinical diagnosis of early manifest HD and a CAG repeat of ≥40. Key eligibility criteria in one presentation included a total functional capacity of 9-13, a diagnostic confidence level of 3 or 4, HD medications stable for the prior 3 months, and striatal volumes exceeding specified minima (putamen ≥ 2.5 cm3/side; caudate ≥ 2.0 cm3/side).
  • Anticipated use: the sponsor states that no available therapy can delay onset or slow progression, and that available symptomatic treatments are only transiently effective and often associated with significant side effects. The sponsor's target profile is a one-time administration of a disease-modifying therapy into the striatum. ICER's assessment names usual symptomatic care (treatment for movement disorders, psychiatric and mood symptoms, physical therapy) as the comparator. A public comment asked ICER to incorporate HD staging (ISS-2 and ISS-3) into the scope, and authors of the HD Integrated Staging System state that it could facilitate trials in populations before clinical motor diagnosis.
Summary: care setting
  • Administration: in the Phase I/II studies, each treated patient received a single administration through MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).
  • Access to specialty care: clinical experts told ICER that about 30% of patients with HD receive specialty care with a movement disorders neurologist, and half of those receive care at an HD Center of Excellence, which raises concern about access to new treatments offered only at specialty centers. A public comment to ICER stated that access is limited to a few neurosurgical centers, that effects beyond four years are unknown, and that there are no retreatment data.
  • Centers of Excellence: there are 60 HDSA Centers of Excellence and 9 Partner Sites covering 37 States plus the District of Columbia, each providing a multidisciplinary team approach. HDSA's comment to ICER states that these centers can inform the treatment burden, access barriers, caregiver requirements, travel, follow-up, and infrastructure needed to deliver a new therapy.
  • Payer analog: Aetna's criteria for eladocagene exuparvovec-tneq (Kebilidi) require precertification, prescription by or in consultation with a neurologist, geneticist, or physician specializing in inherited metabolic diseases, and administration in a medical center that specializes in stereotactic neurosurgery; the policy states that gene and cellular therapies must be administered at an Aetna GCIT Network unless the member's plan has elected otherwise.
Heterogeneity of treatment effect
Summary
  • Dose: the sponsor reports a difference between doses at 48 months in two statements. The third quarter 2026 release states that high-dose patients showed 1.1 points less decline on cUHDRS and 0.33 points less decline on TFC than low-dose patients. The four-year data release reports mean changes from baseline of –0.91 (high dose) and −1.94 (low dose) on cUHDRS, a difference of 1.03, and −0.30 and −0.70 on TFC, a difference of 0.40.
  • Striatal volume: in natural history data presented with the AMT-130 analyses, baseline striatal volume predicted clinical progression in TRACK-HD and predicted cUHDRS decline in the absence of other covariates, and was no longer predictive of cUHDRS or TFC decline when propensity score adjustments were applied. A fourth cohort of six participants with lower striatal volumes than participants in previous cohorts received high-dose AMT-130, with dosing completed in the fourth quarter of 2025.
  • Planned analyses: ICER's research protocol plans, data permitting, to evaluate treatment effect modification by HD stage (HD-ISS stages 2 and 3), concomitant antidopaminergic medication, and striatal volume. ICER's model analysis plan states that no heterogeneity and subgroup analyses are planned because currently available trial data are insufficient to support them. A public comment from Prilenia identified concomitant antidopaminergic medications as a pharmacologically important covariate that a chance imbalance in small studies can shift.
  • Natural history: in a progression model, TFC progression in individuals with HD-ISS 2 is not expected to differ from that in HD-ISS 3, and progression rates correlate weakly between clinical scores. In 960 participants, longer disease duration and better cognitive status at baseline were associated with less rapid TFC decline.
  • Other HD therapies: exploratory GENERATION HD1 analyses suggested benefit in younger participants with lower disease burden, but in GENERATION HD2 the biomarker effects did not translate into a meaningful clinical improvement. For pridopidine, post hoc analyses suggested benefit in participants not receiving antidopaminergic medications, and the European Medicines Agency noted that the validity and relevance of the subgroup results had not been demonstrated.
Care management intervention strategies
Summary
  • Procedure and monitoring analogs: the prescribing information for Kebilidi, a product administered by stereotactic neurosurgery, directs monitoring for procedure-related adverse events, including continuous cardiorespiratory monitoring during hospitalization, and the FDA review states that procedural complications can be mitigated by post-procedural monitoring. Aetna considers brain MRI for stereotactic planning and intraoperative navigation medically necessary for members being considered for Kebilidi.
  • Long-term follow-up: FDA guidance recommends long-term follow-up of up to five years for AAV vectors, with a risk-based approach to duration for vectors capable of long term expression without integration, such as AAV.
  • Multidisciplinary care: a multidisciplinary position paper recommends a multidisciplinary team, an individualised care and treatment plan for every patient and family, and a case manager or coordinator. The Huntington's Disease Society of America states that no one doctor or caregiver should manage all aspects of an HD case, and that the goals of treatment are to reduce the burden of symptoms, maximize function, and optimize quality of life. HDSA Centers of Excellence provide neurologists, psychiatrists, social workers, therapists, counselors, and other professionals.
  • Advance care planning: one guideline describes advance care planning as essential, including discussion of alternative feeding methods, and another recommends documenting living wills and care directives early and social worker support for financial assistance. In one study, engaging in advance care planning did not cause untoward effects on health-related quality of life or suicidal thoughts and behavior (STB), whose lifetime prevalence in HD approaches 30%.
  • Palliative care: a review included 38 of 333 articles and found a low level of evidence for most topics. One publication states that referral to palliative care should be strongly considered for patients with pain, anxiety, sleep disturbances, and difficulty coping with the diagnosis.
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy
Summary
  • Durability: ICER's model analysis plan assumes that the treatment effect remains constant over the lifetime horizon and does not model discontinuation of a one-time gene therapy. Clinical experts noted that because neurons do not divide, the treatment effect may persist, while substantial uncertainty remains around long-term efficacy. ICER models TFC because there is no established mapping from the cUHDRS to costs, utilities, or mortality.
  • Endpoints: a decline of 1.2 points on the cUHDRS is recommended as an estimate of meaningful within-patient decline in early manifest HD. The sponsor reports that the FDA continued to support the cUHDRS as an acceptable registrational, intermediate clinical endpoint for accelerated approval, and a votoplam trial uses change from baseline up to month 36 in the cUHDRS as its primary endpoint. ICER's outcomes of interest include procedure-related adverse events (headache, complications, pain) and post lumbar puncture syndrome.
  • Interpretation of external comparisons: a placebo response in cognitive scores also influences the cUHDRS, and comparisons of trial data with retrospective natural history studies can mislead in distinguishing placebo response from drug effect. FDA draft guidance states that changes in the understanding of a disease's natural history can introduce bias in an externally controlled trial. Of forty-five FDA approvals that accepted external control data, retrospective natural history data were the most common source (44%) and 87% used an objective primary endpoint. Commentators cite a possible medical response bias from more frequent clinic visits, unmatched differences such as caudate and putamen size, and very small numbers of treated patients at longer follow-up, and state that assumptions about how long the benefit lasts will heavily shape modeled results.
  • Modeled long-term outcomes: in one model, hypothetical disease-modifying treatments led to cost savings in the PFD population and increased costs in the SF1 and SF2 populations by prolonging time spent in progressive HD states.